AstraZeneca and Daiichi Sankyo’s Enhertu, in combination with pertuzumab, has been approved by the US FDA to treat adult ...

Discover how AI-powered tools are transforming rare disease diagnosis, patient care, and clinical decision-making.

Health equity is an ambitious goal, but the drive to deliver life-changing innovation to all eligible patients is ...

The industry is now entering the next era by embedding AI directly into the software field teams’ use every day. The step ...

For a child with a rare disease, a doctor’s continuing education can end a years-long diagnostic odyssey and unlock access to ...

How was a new rare disease discovered through Singapore’s Undiagnosed Disease Program? And how will technology allow us to ...

The US FDA has approved the first ever cell-based gene therapy to treat Wiskott-Aldrich syndrome (WAS).

Medicus Pharma has announced the completion of patient enrollment for its phase 2 SKNJCT-003 trial, evaluating the safety and ...

Nektar Therapeutics has announced top-line results from its trial of rezpegaldesleukin to treat severe to very severe ...

What’s holding pharma back from true digital transformation? At NEXT Pharma 2025, Our CEO Rob Verheul and Roeland van der ...

The rise of healthcare content creators and the challenge of misinformation If you work in healthcare and want to see if you ...

Follow-up results from the phase 3 EMBER-3 study showed that, as a monotherapy, Inluriyo demonstrated a 38% reduction in the ...